Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fusion Pharmaceuticals Inc. (FUSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.4000+0.0500 (+2.13%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3500
Open2.3200
Bid2.0100 x 800
Ask2.5400 x 1800
Day's Range2.3000 - 2.5200
52 Week Range1.9800 - 8.7300
Volume84,856
Avg. Volume93,315
Market Cap103.359M
Beta (5Y Monthly)-0.59
PE Ratio (TTM)N/A
EPS (TTM)-1.8250
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.17
  • PR Newswire

    Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 13,200 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employe

  • Zacks

    Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates

    Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • CNW Group

    Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates

    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate developments.

Advertisement
Advertisement